Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

81. Clozapine dose for schizophrenia. Full Text available with Trip Pro

Clozapine dose for schizophrenia. Schizophrenia and related disorders such as schizophreniform and schizoaffective disorder are serious mental illnesses characterised by profound disruptions in thinking and speech, emotional processes, behaviour and sense of self. Clozapine is useful in the treatment of schizophrenia and related disorders, particularly when other antipsychotic medications have failed. It improves positive symptoms (such as delusions and hallucinations) and negative symptoms (...) (such as withdrawal and poverty of speech). However, it is unclear what dose of clozapine is most effective with the least side effects.To compare the efficacy and tolerability of clozapine at different doses and to identify the optimal dose of clozapine in the treatment of schizophrenia, schizophreniform and schizoaffective disorders.We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (August 2011 and 8 December 2016).All relevant randomised controlled trials (RCTs), irrespective

2017 Cochrane

82. Lumateperone for acute exacerbations of psychosis in schizophrenia

Lumateperone for acute exacerbations of psychosis in schizophrenia Lumateperone for acute exacerbations of psychosis in schizophrenia | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs (...) are produced as required for our stakeholders. > > > Lumateperone for acute exacerbations of psychosis in schizophrenia Lumateperone for acute exacerbations of psychosis in schizophrenia May 2017 Lumateperone is a new, orally administered antipsychotic drug which alters levels of several chemicals in the brain including dopamine, serotonin and glutamate. Studies on lumateperone in people with schizophrenia experiencing an episode of severe symptoms suggest it may reduce symptoms with less side effects than

2017 NIHR Innovation Observatory

83. Increases in Intrinsic Thalamocortical Connectivity and Overall Cognition Following Cognitive Remediation in Chronic Schizophrenia Full Text available with Trip Pro

Increases in Intrinsic Thalamocortical Connectivity and Overall Cognition Following Cognitive Remediation in Chronic Schizophrenia Thalamic projections to the prefrontal cortex (PFC) are critical for cognition, and disruptions in these circuits are thought to underlie the pathophysiology of schizophrenia. Cognitive remediation (REM) is a behavioral intervention that holds promise for improving cognition and functioning in schizophrenia, however the extent to which it affects thalamo-prefrontal (...) connections has not been researched. This study sought to determine whether patients with schizophrenia who undergo a placebo-controlled trial of REM show increased functional connectivity between the thalamus and PFC, and whether these changes correspond to improvements in cognition.Twenty-six patients with chronic schizophrenia were randomized to either 48 hours (over 16 weeks) of a drill-and-practice working memory-focused REM or an active placebo condition. All participants underwent cognitive

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging Controlled trial quality: uncertain

84. Impaired suppression of delay-period alpha and beta is associated with impaired working memory in schizophrenia Full Text available with Trip Pro

Impaired suppression of delay-period alpha and beta is associated with impaired working memory in schizophrenia Although people with schizophrenia (PSZ) frequently exhibit reduced working memory capacity relative to healthy comparison subjects (HCS), the mechanisms that underlie this impairment are not yet known. The present study aimed to assess one putative mechanism: impaired suppression of alpha and beta frequency bands during the delay period of a visual working memory task.The

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

85. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Full Text available with Trip Pro

Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels. For these people, a number of treatment strategies have emerged, including the prescription of a second anti-psychotic drug in combination with clozapine.To determine the clinical effects of various clozapine combination strategies with antipsychotic drugs in people (...) with treatment-resistant schizophrenia both in terms of efficacy and tolerability.We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (to 28 August 2015) and MEDLINE (November 2008). We checked the reference lists of all identified randomised controlled trials (RCT). For the first version of the review, we also contacted pharmaceutical companies to identify further trials.We included only RCTs recruiting people of both sexes, aged 18 years or more, with a diagnosis of treatment

2017 Cochrane

86. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. (Abstract)

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Although predominant negative symptoms of schizophrenia can be severe enough to cause persistent impairment, effective treatment options are lacking. We aimed to assess the new generation antipsychotic cariprazine in adult patients with predominant negative symptoms.In this randomised, double-blind, phase 3b trial, we enrolled (...) adults aged 18-65 years with long-term (>2 year), stable schizophrenia and predominant negative symptoms (>6 months) at 66 study centres (mainly hospitals and university clinics, with a small number of private practices) in 11 European countries. Patients were randomly assigned (1:1) by an interactive web response system to 26 weeks of monotherapy with fixed-dose oral cariprazine (3 mg, 4·5 mg [target dose], or 6 mg per day) or risperidone (3 mg, 4 mg [target dose], or 6 mg per day); previous

2017 Lancet Controlled trial quality: predicted high

87. Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T Full Text available with Trip Pro

Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T Examining neurometabolic abnormalities in critical brain areas in schizophrenia and major depressive disorder (MDD) may help guide future pharmacological interventions including glutamate-modulating treatments.To measure metabolite concentrations within the anterior cingulate cortex (ACC) and thalamus of people with schizophrenia and people with MDD.Spectra were acquired from 16 (...) volunteers with schizophrenia, 17 with MDD and 18 healthy controls using magnetic resonance spectroscopy on a 7 Tesla scanner.In the thalamus, there were lower glycine concentrations in the schizophrenia group relative to control (P=0.017) and MDD groups (P=0.012), and higher glutamine concentrations relative to healthy controls (P=0.009). In the thalamus and the ACC, the MDD group had lower myo-inositol concentrations than the control (P=0.014, P=0.009, respectively) and schizophrenia (P=0.004, P=0.002

2017 BJPsych open

88. The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders

The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search (...) Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders David J Castle, Cherrie A Galletly, Frances Dark, Verity Humberstone, Vera A Morgan, Eóin Killackey, Jayashri Kulkarni, Patrick McGorry, Olav Nielssen, Nga T Tran and Assen Jablensky Med J Aust 2017

2017 MJA Clinical Guidelines

89. Outcomes: Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings

Outcomes: Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings | Evidence-Based Mental Health We use cookies to improve our service (...) name or password? You are here Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings Article Text This article has a correction. Please see: Electronic pages Outcomes Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed

2017 Evidence-Based Mental Health

90. Pharmacological interventions: More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia

Pharmacological interventions: More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia

2017 Evidence-Based Mental Health

91. Necessity of oral health intervention in schizophrenic patients - A review Full Text available with Trip Pro

Necessity of oral health intervention in schizophrenic patients - A review Individuals with mental illness often cannot perform day to day activities due to a psychiatric or emotional disorder. Schizophrenia is one such psychiatric disorder characterized by worsening self-care ability with progressing mental illness. This disease may potentially deteriorate oral health by affecting the subject's ability to perform oral hygiene measures. Literature on oral disease manifestations in schizophrenia (...) is limited. Lack of desire for oral health care as well as generally poor awareness of oral health issues in these patients, compounded further by side effects of medications, may complicate dental management in schizophrenic patients. The present review explores clinical features and possible factors associated with oral health status among those with Schizophrenia.

2016 Nepal journal of epidemiology

92. 29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report Full Text available with Trip Pro

29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report Multiple sclerosis (MS) is the most common debilitating neurological disease that affects adults, whether young adults or middle-aged. Although, most attention is toward the neurological signs of the disease, the neuropsychiatric signs are not uncommon. This case report presents a 29 year old male with a record of obsessive-compulsive disorder (OCD) without psychotic disorder, which coincides with the diagnosis MS, has (...) of schizophrenia which was confirmed in subsequent visits. The signs of the patient were not controllable for a long time and finally fully controlled by a combination of Aripiprazole (abilizol), Risperidone and Sertraline, and currently, for almost 3 years, both psychotic symptoms and MS disease have been under control. Our patient seems to catch the MS disease and schizophrenia simultaneously. There was no relation between MS and psychosis episodes and the MS attacks. Since the onset the patient had several

2016 Electronic physician

93. Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report Full Text available with Trip Pro

Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report There is currently limited experience in the initiation and maintenance of clozapine for treatment-resistant psychosis in adults with established structural heart disease. These complex patients require close supervision and liaison between colleagues. Here we present the successful experience of treating one such patient within our service and describe a monitoring plan to ensure (...) that these treatments can be provided both safely and effectively.A 36-year-old man with treatment-resistant schizophrenia and known hypertrophic cardiomyopathy (HCM) was admitted to a specialist unit for a trial of clozapine. His psychiatric illness was characterised by multimodal hallucinations and delusions combined with low mood and poor motivation. The diagnosis of HCM was made 3 years previously following a routine electrocardiogram (ECG), and he had remained asymptomatic throughout this time; there were

2016 BJPsych open

94. Integrated supported employment plus cognitive remediation training for people with schizophrenia. (Abstract)

Integrated supported employment plus cognitive remediation training for people with schizophrenia. 26908337 2016 12 13 2016 12 30 1024-2708 22 Suppl 2 2016 Feb Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Integrated supported employment plus cognitive remediation training for people with schizophrenia. S15-8 Tsang H W H HW Neuropsychiatric Rehabilitation Laboratory, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong. Bell M D MD (...) methods Employment, Supported methods Executive Function Female Hong Kong Humans Male Middle Aged Psychiatric Status Rating Scales Schizophrenia rehabilitation Social Skills 2016 2 25 6 0 2016 2 26 6 0 2016 12 15 6 0 ppublish 26908337

2016 Hong Kong medical journal = Xianggang yi xue za zhi Controlled trial quality: uncertain

95. Contribution of oxytocin receptor polymorphisms to amygdala activation in schizophrenia spectrum disorders Full Text available with Trip Pro

Contribution of oxytocin receptor polymorphisms to amygdala activation in schizophrenia spectrum disorders Oxytocin has been proposed to mediate amygdala dysfunction associated with altered emotion processing in schizophrenia, but the contribution of oxytocin pathway genes is yet to be investigated.To identify potential different contributions of three oxytocin receptor polymorphisms (rs53576, rs237902 and rs2254298) between patients with schizophrenia spectrum disorders (SCZ), affective

2016 BJPsych open

96. Effect of transcranial direct current stimulation (tDCS) over the prefrontal cortex combined with cognitive training for treating schizophrenia: a sham-controlled randomized clinical trial. Full Text available with Trip Pro

Effect of transcranial direct current stimulation (tDCS) over the prefrontal cortex combined with cognitive training for treating schizophrenia: a sham-controlled randomized clinical trial. We report a transcranial direct current stimulation (tDCS) protocol over the dorsolateral prefrontal cortex (DLPFC) combined with cognitive training in schizophrenia.We assessed psychotic symptoms in nine patients using the Positive and Negative Syndrome Scale (PANSS). All evaluations were scored at baseline (...) severity scores (p = 0.619). Mixed analysis of variance (ANOVA) showed no statistical significance between the groups regarding final PANSS scores.The results failed to demonstrate that the concomitant use of tDCS and cognitive training is effective to improve clinical outcomes in patients with schizophrenia. The present findings should be analyzed with care, considering the small sample size. Larger controlled trials on electric/cognitive stimulation should be produced in order to enhance therapeutic

2016 Trends in psychiatry and psychotherapy Controlled trial quality: uncertain

97. Loss of relational continuity of care in schizophrenia: associations with patient satisfaction and quality of care Full Text available with Trip Pro

Loss of relational continuity of care in schizophrenia: associations with patient satisfaction and quality of care Users of mental health service are concerned about changes in clinicians providing their care, but little is known about their impact.To examine associations between changes in staff, and patient satisfaction and quality of care.A national cross-sectional survey of 3379 people aged 18 or over treated in secondary care for schizophrenia or schizoaffective disorder.Nearly 41.9 (...) continuity of care for such patients.M.J.C. was co-chair of the expert advisory group on the NICE quality standard on Service User Experience in Adult Mental Health. S.J.C. has previously been a member of the Health and Social Care Board Northern Ireland Formulary Committee. D.S. received a speaker's fee from Janssen Cilag in 2011. He is a topic expert on NICE guideline for psychosis and schizophrenia in children and young people and a board member of National Collaborating Centre for Mental Health.©

2016 BJPsych open

98. Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. Full Text available with Trip Pro

Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. Clozapine causes significant metabolic disturbances including obesity and type 2 diabetes. Recent evidence that reduced glucagon-like-peptide-1 (GLP-1) may contribute to aetiology of clozapine-associated metabolic dysregulation suggests a potential therapeutic role for GLP-1 agonists.This open-label, pilot randomised controlled trial (...) evaluates the effect of exenatide in clozapine-treated obese adults who have schizophrenia, with or without poorly controlled diabetes. Sixty out-patients will be randomised to once weekly extended release exenatide or treatment as usual for 24 weeks.To evaluate the feasibility of larger studies regarding methodology, acceptability, tolerability and estimate efficacy for glycaemic control or weight loss. Secondary outcomes are psychosis severity and metabolic parameters.This is the first trial

2016 BJPsych open Controlled trial quality: uncertain

100. Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. Full Text available with Trip Pro

Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. Psychiatric symptoms in individuals who use ketamine versus methamphetamine—implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study - The Lancet Go search This Journal Full Site Access provided by , S67, October 01, 2016 Powered By Mendeley Psychiatric symptoms in individuals who use ketamine versus (...) methamphetamine—implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study Yanhui Liao Affiliations Mental Health Institute of the Second Xiangya Hospital, Central South University, Hunan 410011, China National Clinical Research Center on Mental Disorders & National Technology Institute on Mental Disorders, Hunan 410011, China Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China Chang Qi Affiliations Mental Health Institute of the Second Xiangya

2016 Lancet